Study of DC-CIK to Treat Colorectal Cancer
NCT01839539 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 60
Last updated 2013-04-25
Summary
The purpose of this study is to evaluate the efficacy of dendritic and cytokine-induced killer cells (DC-CIK) for colorectal cancer (CRC).
Conditions
Interventions
- BIOLOGICAL
-
dendritic and cytokine-induced killer cells
Sponsors & Collaborators
-
Guangxi Medical University
lead OTHER
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2013-03-31
- Primary Completion
- 2018-03-31
- Completion
- 2018-03-31
Countries
- China
Study Locations
More Related Trials
-
Safety of Labeled Dendritic Cell (DC) Vaccines and Feasibility of Tracking by Magnetic Resonance Imaging (MRI)
NCT01671592 ·Status: COMPLETED ·Phase: PHASE1
-
DC Vaccine Combined With CIK Cells in Patients With Renal Cell Carcinoma
NCT01924156 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Clinical Study of DC-CIK Cells as a Post-remission Treatment for Malignant Tumors
NCT04292769 ·Status: UNKNOWN ·Phase: PHASE3
-
Immunotherapy for Colorectal Cancers Using CEA-Pulsed Dendritic Cells and Subsequent IL-2 Treatment
NCT00154713 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Cytokine Induced Killer Cells Stimulated by DC Immunotherapy for Renal Cell Carcinoma
NCT01240005 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Clinical Safety and Preliminary Efficacy of AAV-DC-CTL Treatment in Stage IV Gastric Cancer
NCT01637805 ·Status: UNKNOWN ·Phase: PHASE1
-
Engineered Immune Effectors Against Cervical Cancer
NCT03362619 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Study With Dendritic Cell Immunotherapy in Resected Hepatic Metastasis of Colorectal Carcinoma
NCT01348256 ·Status: UNKNOWN ·Phase: PHASE2
-
Dendritic Killer Cell-based Immunotherapy for Solid Tumors
NCT02882659 ·Status: UNKNOWN ·Phase: PHASE1
-
DC Vaccine Combined With CIK Cells in Patients With Esophagus Cancer
NCT02693236 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Study of DC-CIK Combined With Chemotherapy for Advanced Solid Tumor
NCT04214717 ·Status: UNKNOWN ·Phase: NA
-
Dendritic Cell Vaccination in Patients With Advanced Colorectal Cancer
NCT00311272 ·Status: COMPLETED ·Phase: PHASE2
-
Intervention of CAR-T Against Cervical Cancer
NCT03356795 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Phase I Trial of CEA Specific AAV-DC-CTL Treatment in Stage IV Gastric Cancer
NCT02496273 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Dendritic Cell-based Immunotherapy in Treatment Gastric Cancer
NCT03410732 ·Status: UNKNOWN ·Phase: PHASE2
-
TSA-DC Vaccine in Treating Patients With Gastrointestinal Solid Tumor
NCT03185429 ·Status: UNKNOWN ·Phase: NA
-
Clinical Efficacy and Safety of Dendritic Cytotoxic Lymphocyte(DC-CTL) Cell Infusion in NSCLC Patients
NCT02766348 ·Status: UNKNOWN ·Phase: PHASE2
-
Dendritic Cell (DC) Activated Cytokine-induced Killer Cell (DCIK) Combined With DC Treatment for Glioma
NCT01235845 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
T Cell Receptor Gene Therapy Targeting KK-LC-1 for Gastric, Breast, Cervical, Lung and Other KK-LC-1 Positive Epithelial Cancers
NCT05035407 ·Status: TERMINATED ·Phase: PHASE1
-
Dendritic Cell Vaccine Study (DC/PC3) for Prostate Cancer
NCT00345293 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Alpha-type-1 Dendritic Cell-based Vaccines in Patients With Metastatic Colorectal Cancer
NCT00558051 ·Status: COMPLETED ·Phase: PHASE1
-
Tumor-Pulsed Dendritic Cells Used as a Tumor Vaccine
NCT00176761 ·Status: TERMINATED ·Phase: PHASE2
-
Gene Expression Profiling of Malignant Tumor Predict the Therapeutic Response of DC-CIK Immunotherapy
NCT01906632 ·Status: COMPLETED ·Phase: NA
-
DC Vaccine Combined With IL-2 and IFNα-2a in Treating Patients With mRCC
NCT00085436 ·Status: COMPLETED ·Phase: PHASE2
-
DC Vaccine Combined With CIK Cells in Patients With SCLC
NCT02688673 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2